Owens & Minor, Inc. Hits New 52-Week Low at $3.76

Owens & Minor, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 3.76 as of October 31, 2025. This significant drop highlights the company's ongoing struggles, with a staggering one-year performance decline of 76.81%, starkly contrasting with the S&P 500's gain of 19.89% during the same period. The company's market capitalization stands at USD 416 million, and it currently exhibits a price-to-earnings (P/E) ratio of 6.00. However, Owens & Minor's financial metrics reveal challenges, including a negative return on equity of -76.43% and a concerning debt-to-equity ratio of -7.06. The stock's price-to-book ratio is also negative at -1.48, indicating potential issues with asset valuation. Despite a 20.30% compound annual growth rate in operating profits over the last five years, the company faces difficulties in servicing its debt, as evidenced by a high debt-to-EBITDA ratio of 4.13 times. The recent performance underscores a consistent underperformance against market benchmarks, raising questions about the company's long-term viability in a competitive industry.